ArticleExperimental and therapeutic medicine2019
HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Combined general and neuraxial anesthesia versus general anesthesia alone for laparoscopic cholecystectomy: a meta-analysis of pain control and hemodynamic stability.Updates in surgery · 2026Pooled it
- Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A-Dependent CXCL5 Upregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- HOX and MEINOX in cellular plasticity, fibrosis, and cancer.World journal of stem cells · 2025Review
- The role of HOXA1 in cancer and targeted therapy.Medical oncology (Northwood, London, England) · 2025Review
- O-prenylchalcones inhibit cell proliferation and activate apoptosis by inducing mitochondrial dysfunction in gastric cancer cells.Discover oncology · 2025Article
- Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival.Cell death and differentiation · 2025Article
- Intracellular galectin interactions in health and disease.Seminars in immunopathology · 2024Review
- A retinoid analogue, TTNPB, promotes clonal expansion of human pluripotent stem cells by upregulating CLDN2 and HoxA1.Communications biology · 2024Article
- Role of HOXA1-4 in the development of genetic and malignant diseases.Biomarker research · 2024Review
- KnockTF 2.0: a comprehensive gene expression profile database with knockdown/knockout of transcription (co-)factors in multiple species.Nucleic acids research · 2024Article
- Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.Biomolecules · 2023Review
- Review
- The Role of Different Types of microRNA in the Pathogenesis of Breast and Prostate Cancer.International journal of molecular sciences · 2023Review
- Genetic analysis of a malignant meningioma and associated metastases.Acta neurochirurgica · 2022Article
- Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.Aging · 2022Article
- The Diagnostic and Prognostic Values of HOXA Gene Family in Kidney Clear Cell Renal Cell Carcinoma.Journal of oncology · 2022Article
- MYC/MAX-Activated LINC00958 Promotes Lung Adenocarcinoma by Oncogenic Transcriptional Reprogramming Through HOXA1 Activation.Frontiers in oncology · 2022Article
- CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis.Bioengineered · 2021Article
- MiR-10a-5p restrains the aggressive phenotypes of ovarian cancer cells by inhibiting HOXA1.The Kaohsiung journal of medical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-associated mortality among females worldwide. As a member of the homeobox (HOX) gene family, HOXA1 is involved in tumor progression and prognosis in several types of human cancer. However, the clinical significance and biological functions of HOXA1 in BC remains unknown. The current study assessed the expression of HOXA1 in BC tissues and cells via western blotting and reverse transcription-quantitative polymerase chain reaction. The association between HOXA1 expression and the clinicopathological features of patients with BC was analyzed using the Chi-square test. The overall survival of patients was calculated using the Kaplan-Meier method and examined using the log-rank test. Cell proliferation was examined via an MTT assay. Cell cycle distribution and cell apoptosis were analyzed using flow cytometry. The current study demonstrated that HOXA1 mRNA and protein expression was upregulated in BC. In addition, HOXA1 overexpression was associated with poor prognosis and advanced clinicopathological features in patients with BC. Furthermore, knockdown of HOXA1 significantly inhibited cell proliferation by enhancing cell apoptosis and cell cycle arrest in BC cells, which was accompanied with aberrant expression of cell cycle and apoptosis-associated proteins, cyclin D1, B-cell lymphoma 2 (Bcl-2) and Bcl-2-like protein 4. Taken together, the results suggested that HOXA1 may serve as a novel prognostic marker and therapeutic target in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.